Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

,095 178,179

-------------------------------------------------------------------------

Manufacturing and related process

development expenses 879,937 1,259,716

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the third quarter of 2007, our M&P expenses decreased to $879,937 compared to $1,259,716 for the third quarter of 2006. In the third quarter of 2007, we continued to fill, test, and package the REOLYSIN(R) that was produced earlier in the year. During the third quarter of 2006, we commenced a number of cGMP production runs using our improved manufacturing process. The technology transfer of our improved process was successfully completed at the beginning of the third quarter of 2006.

Our process development studies in the third quarter of 2007 focused on increasing the scale of our production runs from batch sizes of 20 litres to 40 and then 100 litres. In the third quarter of 2006, we completed process development studies that were successful in improving virus yields.

Clinical Trial Program

2007 2006

$ $

-------------------------------------------------------------------------

Direct clinical trial expenses 1,201,557 639,719

Other clinical trial expenses 76,618 48,716

-------------------------------------------------------------------------

Clinical trial expenses 1,278,175 688,435

-------------------------------------------------------------------------

-------------------------------------------------------------------------

During the third quarter of 2007, our direct clinical trial expenses increa
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ... June 26, 2015 , ... ReliantHeart, Inc. , an innovative ... the first implant of the HeartAssist5® LVAD (HA5) to the 68th consecutive implant, there ... Thrombus that originates in an LVAD is referred to as de novo thrombus. De ...
(Date:6/25/2015)... 2015 Current asthma medications, which work ... by dilating the airways, can stop working over ... and Women,s Hospital and Harvard Medical School supports ... certain sensory nerve endings in the lungs that ... in the journal Neuron on June ...
(Date:6/25/2015)... 2015  BioMed Realty Trust, Inc. (NYSE: BMR ... ), a world leader in genomics focused on improving ... has signed a 20-year lease for a 155,000 square ... Cambridge, England . The project will provide ... skilled workforce in the dynamic research cluster anchored by ...
(Date:6/25/2015)... Israel , June 25, 2015 ... investors to co-invest with Startup Nation,s leading angels and ... appointment of Darya Fuks as Portfolio Manager.  ... Investment Bank, will lead iAngels, deal flow and due ... development efforts for all iAngels portfolio companies. An investment ...
Breaking Biology Technology:HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3Targeting Nerve Endings To Curb Allergic Asthma 2Targeting Nerve Endings To Curb Allergic Asthma 3Targeting Nerve Endings To Curb Allergic Asthma 4Targeting Nerve Endings To Curb Allergic Asthma 5BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 2BioMed Realty And Illumina Announce New Build-To-Suit Laboratory Building In Cambridge's Growing Life Science Cluster 3Former J.P. Morgan Vice President Darya Fuks Joins iAngels 2Former J.P. Morgan Vice President Darya Fuks Joins iAngels 3
... Dendreon Corporation (Nasdaq: DNDN ) management will host a conference call ... second quarter 2009 financial results. Access to the discussion may be obtained as ... 11:30 AM ET /8:30 AM PT, Date: ... (domestic) or +1-719-325-4873 (international), Webcast: www.dendreon.com (homepage and investor ...
... , , , PITTSBURGH, July 30 ... the three and six months ended June 30, 2009. , , ... Adjusted diluted EPS, which excludes the impact of certain purchase accounting items ... $0.65 for the three and six months ended June 30, 2009, compared to $0.20 ...
... a weakened strain of the malaria parasite that will be ... developed in collaboration with researchers from the US, Japan and ... Malaria kills more than one million people each year and ... of at least 35 million years of healthy, productive human ...
Cached Biology Technology:Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 2Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 3Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 4Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 5Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 6Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 7Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 8Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 9Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 10Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 11Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 12Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 13Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 14Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 15Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 16Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 17Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009 18First genetically engineered malaria vaccine to enter human trials 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... protective delivery vehicle that shuttles friendly bacteria safely through ... boost for the probiotics industry. The new technology ... drugs and even increase calcium absorption, according to research ... at the University of York this week. The ...
... coli strain that hit Germany in May 2011 ... of collaboration across the scientific community should give insight ... the Society for General Microbiology,s Autumn Conference 2011. ... BGI, China. Their sequence was provided in draft form ...
... this math more evident than in vertebrates, which are programmed ... do not. Snakes, of course, have no digits, and birds ... handle on how these developmental changes are orchestrated in the ... Which digits are they: a thumb with index and middle ...
Cached Biology News:New polymer research could boost probiotics industry 2Crowd-sourcing the E. coli O104:H4 outbreak 2
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... (BTI-TN-5B1-4) derived from Trichoplusia ni egg ... be capable of expressing significantly higher ... to other insect cells. High Five ... time as adherent cultures- Quick adaptation into ...
... Racks are ideal for storage and transport ... polypropylene racks withstand extreme temperatures, making them ... may also be autoclaved for use in ... side accommodates 0.5ml microcentrifuge tubes, the other ...
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Biology Products: